cdk4/6 inhibitors in her2-negative breast cancer based on phase iii monaleesa-7 trial
Published 5 years ago • 153 plays • Length 0:37Download video MP4
Download video MP3
Similar videos
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
2:19
cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
6:05
cdk4/6 inhibitors & endocrine therapy: selecting a regimen
-
4:52
cdk4/6 inhibitors in hormone receptor-positive, her2-negative metastatic breast cancer
-
2:55
practical implications of the monaleesa-3 trial
-
6:46
cdk4/6 inhibitors & endocrine therapy: treatment resistance
-
0:14
cdk4/6 inhibitors: a new class of drugs for cancer treatment
-
4:37
case 2: cdk4/6 inhibitors in er breast cancer
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
4:15
case 2: choosing a cdk4/6 inhibitor in er breast cancer
-
1:33
ongoing trial of abemaciclib and pembrolizumab in hr /her2-negative breast cancer
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
6:13
case 2: cdk4/6 inhibitor recommendations in er breast cancer
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference